ARS Pharmaceuticals Hits 52-Week Low at $6.16 Amid Financial Struggles

ARS Pharmaceuticals, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.16 on July 21, 2026. This decline marks a significant downturn for the company, which has seen its stock price drop by 29.88% over the past year, contrasting sharply with the S&P 500's performance of 19.09% during the same period. The company's market capitalization stands at USD 801 million, and it has faced considerable financial challenges, reporting negative results for the last four consecutive quarters. Notably, net sales for the half-year period were USD 50.77 million, reflecting a decline of 46.31%. Additionally, the operating cash flow has reached a low of USD -175.07 million, and the return on capital employed (ROCE) is at a concerning -136.4%. With a price-to-book ratio of 7.01 and a debt-to-equity ratio of -1.30, ARS Pharmaceuticals is navigating a challenging financial landscape. The stock's performance has been below par both in the near term and long term, raising concerns about its market position and sustainability.